Headlines

PROFORMANT, INC. PUBLISHES ITS 2003 PULMONARY BIOPHARMACEUTICALS OUTLOOK.

Biomedical corporate development consultancy PROFORMANT, Inc. reviews technical and clinical performance considerations of selected later-stage inhalation formulations.

Framingham, MA, October 21, 2002 — PROFORMANT, Inc. a biomedical corporate development consultancy, announced today the publication of its 2003 Pulmonary Biopharmaceuticals Outlook.  The report summarizes key technical and clinical performance considerations for inhalation pharmaceuticals, and it identifies products in the pipeline for several leading indications.  In addition, the report highlights some of the unique regulatory issues faced by inhalation formulations.

PROFORMANT, Inc. Managing Partner, Joseph Kozikowski, M.D., presented the report at the Academy of Managed Care Pharmacy 2002 Education Conference in Washington, D.C. earlier this month.

About PROFORMANT, Inc.

PROFORMANT delivers expertise and strategic consulting that enables pharmaceutical, biotechnology, medical device, and diagnostics companies to achieve new milestones of growth, competitive advantage, and value.

Visit PROFORMANT online at www.proformant.com

For further information, please contact:

Danielle LeBon
Communications Manager
PROFORMANT, Inc.
dlebon@proformant.com
508.872.2725 x104
(Framingham, MA)